Clinical Trials | September 23, 2025
Roche's Giredestrant combination meets phase III endpoints in advanced breast cancer
Importantly, the combination of giredestrant and everolimus was well tolerated
Importantly, the combination of giredestrant and everolimus was well tolerated
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
This predictive technology empowers people with diabetes to take preventive action before complications arise
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
Encouraging early detection and breaking the silence around men’s health
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
The state-of-the-art facility is a 450-bedded, multi-specialty tertiary care hospital,
Subscribe To Our Newsletter & Stay Updated
